UnicoCell Biomed has made a big step forward in stem cell therapy

2022-12-01

Source: UnicoCell Biomed Co.,Ltd ( Healthcare+ Expo- booth no.:   J618 )

UnicoCell Biomed Company Ltd. ("UnicoCell”) is a new drug development company dedicating to stem cell therapy and its derived technology over a decade. We focus on degenerative diseases with unmet medical needs. The new drug candidate, ELIXCYTE® of UnicoCell, an allogeneic cell product, has evaluated on human clinical trials for knee osteoarthritis (OA knee) and chronic kidney disease (CKD). Current data of the above trials reveal the safety and efficacy of ELIXCYTE® in clinical application and have been published in international journals.

 

In 2022, we have made a big step forward in submitting a phase three clinical trial of OA knee to USFDA and TFDA, and have completed the recruitment of the phase I/II clinical trial of CKD. In addition, as a pioneer of stem cell therapy in Taiwan, UnicoCell collaborated with hospitals in pre-clinical therapeutic study of treating retinal degenerative diseases and chronic wound with allogeneic stem cells.

 

Moreover, UnicoCell has built a comprehensive cell bank following the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH). This will be potential candidates for regenerative medicine and an excellent source of starting material for researchers and physician.

 

We have designed a robust quality system in our facility which has been certified with GTP and CPU by TFDA, CPC by PMDA Japan and ISO/IEC 17025 testing Lab. And a new facility has built following PIC/S GMP standards will be able to provide CDMO services.

 

Additionally, to ensure the safety and security of therapeutic products, UnicoCell has designed a cryogenic vial- UnicoVial®, has been approved by TFDA as a class II medical device, designed for storage of cell products and biological samples under ultra-low temperature and with the patented design, UnicoVial® is convenient for clinical use.

 

Taken together, the ELIXCYTE®, allogeneic cell banks, UnicoVial®, cell related products and services, UnicoCell provides the total solution for the regenerative medicine and was honored with various awards in the past two years, including Gold Award of the Pharmaceutical Technology & Research Development Award (Ministry of Health and Welfare and the Ministry of Economic Affairs), Golden Boat Award (General Chamber of Commerce of the Republic of China), and 19th Innovation Award (Institute for Biotechnology and Medicine Industry).

 

UnicoCell is your best and reliable partner in the field of stem cells.

 

Visit UnicoCell booth to learn more about the leading allogeneic adipose stem cell bank, Gold Award new stem cell drug ELIXCYTE® and patented UnicoVial®, certified class II medical device for storage of cell products and biological samples for clinical use.

 

Exhibition: December 1-4, 2022

Location: Hall 1, Taipei Nangang Exhibition Center (TaiNEX1)

Booth: J618 (J area inside E-Da Health Group booth)